Mendus
Clinical-stage company developing immunotherapies to prevent tumor recurrence.
IMMU | ST
Overview
Corporate Details
- ISIN(s):
- SE0005003654 (+1 more)
- LEI:
- 529900AFBGFR7ZB50J95
- Country:
- Sweden
- Address:
- Västra Trädgårdsgatan 15, 111 53 Stockholm
- Website:
- https://mendus.com/
- Sector:
- Manufacturing
Description
Mendus is a clinical-stage company developing immunotherapies to improve long-term survival for cancer patients. The company's primary focus is on preventing tumor recurrence, a leading cause of cancer-related mortality. By leveraging its expertise in allogeneic dendritic cell biology, Mendus designs therapies that stimulate the immune system to build active and long-lasting immunity against residual cancer cells. This approach aims to change the course of cancer treatment by offering durable responses while preserving the patient's quality of life. The company's pipeline is centered on maintenance therapies for various forms of cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2018-12-12 13:34 | English | PDF • 35.3 KB | |||
| 2018-12-06 17:42 | English | PDF • 35.3 KB | |||
| 2018-11-23 11:15 |
Immunicum offentliggör prospekt i samband med företrädesemission och riktad emi…
|
Swedish | PDF • 105.7 KB | ||
| 2018-11-23 11:15 |
Immunicum AB (publ) Publishes Prospectus in Connection with Rights Issue and Di…
|
English | PDF • 104.2 KB | ||
| 2018-11-16 08:30 |
Immunicum tillkännager samarbete med Merck KGaA, Darmstadt, Tyskland och Pfizer…
|
Swedish | PDF • 103.6 KB | ||
| 2018-11-16 08:30 |
Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany…
|
English | PDF • 121.0 KB | ||
| 2018-11-12 13:08 | English | PDF • 35.3 KB | |||
| 2018-11-08 16:31 |
Kommuniké från extra bolagsstämman i Immunicum AB (publ) den 8 november 2018
|
Swedish | PDF • 79.5 KB | ||
| 2018-11-08 16:31 |
Report from Extraordinary General Meeting of Immunicum AB (publ) on 8 November …
|
English | PDF • 119.2 KB | ||
| 2018-11-07 08:01 | Swedish | PDF • 762.8 KB | |||
| 2018-11-07 08:01 | English | PDF • 705.3 KB | |||
| 2018-11-05 12:40 | English | PDF • 35.3 KB | |||
| 2018-10-30 13:09 | English | PDF • 35.3 KB | |||
| 2018-10-26 14:30 | English | PDF • 35.4 KB | |||
| 2018-10-19 08:00 |
Valberedning utsedd inför Immunicum ABs årsstämma 2019
|
Swedish | PDF • 65.2 KB |
Automate Your Workflow. Get a real-time feed of all Mendus filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Mendus
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Mendus via our API.
Peer Companies
